Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564687 | 0.89 | VDR (0.41) | VDRHDAC3HDAC6FFAR4 | |
| SCHEMBL6385965 | 0.78 | HPGD (0.40) | VDRFFAR4FFAR1HPGD | |
| SCHEMBL5569702 | 0.78 | FFAR4 (0.48) | FFAR4FFAR1HPGD | |
| SCHEMBL5565459 | 0.77 | VDR (0.53) | VDRHDAC3HDAC6 | |
| SCHEMBL5570821 | 0.76 | VDR (0.41) | VDRHDAC3HDAC6FFAR4FFAR1 | |
| SCHEMBL5568696 | 0.74 | FFAR4 (0.37) | VDRFFAR4FFAR1HPGDFFAR2 | |
| SCHEMBL5564748 | 0.72 | MAPT (0.39) | FFAR4FFAR1HPGD | |
| SCHEMBL6390211 | 0.71 | PPARA (0.48) | FFAR4FFAR1HPGD | |
| SCHEMBL5569766 | 0.71 | ESR1 (0.52) | VDR | |
| SCHEMBL5971611 | 0.71 | VDR (0.48) | VDRHDAC3HDAC6FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | claimed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | claimed |
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537065-A1 | ANALOGUES OF VITAMIN D | Galderma Research & Development, S.N.C. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020379-A1 | ANALOGUES OF VITAMIN D | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | VDR 3/4885HDAC3 2976/4885HDAC6 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.